For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Sorafenib | * Cycle 1: 400 mg BID sorafenib * Cycle 2: 600 mg BID sorafenib * Cycle 3+: 800 mg BID sorafenib Sorafenib: Sorafenib administered in escalating 28-days cycles (400, 600 and 800 mg BID) | None | None | 0 | 9 | 9 | 9 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| General disorders and administration site conditions-other, Hand foot Syndrome | None | General disorders | CTCAEv4 | View |
| Rash maculo-papular | None | Skin and subcutaneous tissue disorders | CTCAEv4 | View |
| Pruritus | None | Skin and subcutaneous tissue disorders | CTCAEv4 | View |
| Diarrhea | None | Gastrointestinal disorders | CTCAEv4 | View |
| Hypertension | None | Vascular disorders | CTCAEv4 | View |
| Alopecia | None | Skin and subcutaneous tissue disorders | CTCAEv4 | View |
| Hypercalcemia | None | Metabolism and nutrition disorders | CTCAEv4 | View |
| Fatigue | None | General disorders | CTCAEv4 | View |
| Arthralgia | None | Musculoskeletal and connective tissue disorders | CTCAEv4 | View |
| Dry skin | None | Skin and subcutaneous tissue disorders | CTCAEv4 | View |
| Nausea | None | Gastrointestinal disorders | CTCAEv4 | View |
| Dysgeusia | None | Nervous system disorders | CTCAEv4 | View |
| Weight loss | None | Investigations | CTCAEv4 | View |
| Oral pain | None | Gastrointestinal disorders | CTCAEv4 | View |
| Flatulence | None | Gastrointestinal disorders | CTCAEv4 | View |
| Flushing | None | Vascular disorders | CTCAEv4 | View |